Director / Senior Director of Strategic Pricing, Government Pricing, and GPO

Overview

Position : Director / Senior Director of Strategic Pricing, Government Pricing, and GPO

Department : Market Access

Reports to : Senior Vice President, Market Access & Alliance Management

Location : Hybrid (Boston Seaport Office)

Job Summary :

The Director / Senior Director of Strategic Pricing, Government Pricing, and GPO will serve as a key leader within the Commercial organization, responsible for developing and executing pricing strategies for our existing and pipeline products. The role will be tasked with maximizing patient access and net revenue, managing gross-to-net (GTN) inclusive of forecasts and liabilities, ensuring compliance with federal and state regulations—including Inflation Reduction Act (IRA) rebate reporting—and optimizing performance across Group Purchasing Organization (GPO) channels. This role requires deep expertise in government program pricing, GTN management, strategic pricing analytics, and commercial contracting with a focus on driving sustainable value creation for the business while ensuring robust patient access.

Key Responsibilities :

Strategic Pricing & Contracting

• Lead development and implementation of pricing strategies, balancing patient access, payer dynamics, and company financial objectives
• Evaluate competitive pricing & market dynamics to inform strategic decision-making
• Partner with Market Access, Finance, and Marketing personnel to align pricing strategies with business objectives and product lifecycle plans
• Oversee commercial contracting strategy and execution for GPOs and key institutional customers, ensuring accurate price loading in the marketplace
• Lead the presentation of pricing committee recommendations

Government Pricing & Compliance

Gross-to-Net (GTN) Management

GPO & Channel Strategy

Cross-Functional Collaboration

Qualifications

AVEO Oncology ("AVEO") is an oncology-focused biopharmaceutical company committed to providing innovative solutions to improve cancer patients lives. On January 20, 2023, AVEO was acquired by LG Chem, Ltd. ("LG Chem"), establishing a U.S. commercial presence for LG Chem and expanding LG Chem\'s global oncology portfolio. AVEO continues to commercialize FOTIVDA (tivozanib) in the U.S. To learn more about FOTIVDA efficacy, safety, and relevant resources, visit FOTIVDAHCP.com.

All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran.

#J-18808-Ljbffr